Surrozen FDA clears IND for SZN-8141 in diabetic macular edema
Regulatory clearance lets Surrozen advance SZN-8141 into clinical development for diabetic macular edema.
Story updates
12:09:05 PM UTC
SquawkNews
Surrozen secured FDA IND clearance for SZN-8141 for diabetic macular edema and expects the second closing of its March 2025 private placement to provide approximately $95.1M in gross proceeds on or about Oct. 20, 2026, subject to conditions.Material DetailsContext by AI AnalystThis is an early clin…